The bottleneck in In Vivo CAR T may be delivery rather than the CAR itself. This article examines ERTLNP, T-cell activation, mTOR signaling, CMC implications, and the emerging 2026 clinical landscape.

Executive Summary Pfizer has introduced a new platform called USTAT (Unified Sequential Template Amplification and Transcription). The platform uses Rolling Circle Amplification (RCA) to establish an mRNA manufacturing process that does not rely on traditional plasmid DNA. The time from DNA template generation to mRNA production can potentially be reduced to approximately two days. RNA quality approaches that of conventional plasmid DNA-based manufacturing, although challenge